Yahoo Finance 
Global Influenza Vaccines Market Report 2022-2028: Increasing Government Support to Promote Influenza Vaccination and Rising Investments by Top Market Players
Global Influenza Vaccines Market
Dublin, Sept. 05, 2022 (GLOBE NEWSWIRE) -- The "Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Vaccine Type, Virus Type, Technology, and Route of Administration" report has been added to ResearchAndMarkets.com's offering.
The influenza vaccines market is expected to grow from US$ 7,478.53 million in 2021 to US$ 12,272.49 million by 2028. It is expected to grow with a CAGR of 7.4% from 2022 to 2028.
Increasing government support to promote influenza vaccination and rising investment by top market players and governments are the major factors boosting the market.
The governments of various states are supporting the promotional activities of vaccination program. For instance, the Australian government gives a free seasonal influenza vaccine to those at risk of influenza-related complications through the National Immunization Program (NIP). By 2022, enough vaccines have been given to cover all risk groups eligible for a government-funded flu vaccine through the NIP.
Vaccine Type Insights
Based on the vaccine type, the influenza vaccines market is segmented into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment is likely to hold a larger market share in 2022.
The same segment is anticipated to register a higher CAGR during the forecast period. The quadrivalent influenza (flu) vaccine protects against 4 influenza viruses, including 2 influenza A viruses and 2 influenza B viruses. All flu vaccines in the US during the 2021-2022 season are quadrivalent vaccines. Different vaccines are approved for different age groups.
Virus Type Insights
Based on virus type, the influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment is likely to hold a larger market share in 2022. The same segment is expected to record a faster CAGR during the forecast period. The market growth of the influenza virus type A segment is because it is the most common form of influenza and can infect animals, although illnesses associated with this type of flu are more common.
Technology Insights
Based on technology, the influenza vaccines market is segmented into egg-based and cell-based. The egg-based segment is likely to hold a larger market share in 2022. The same segment is expected to record a faster CAGR during the forecast period.
The market growth of the egg-based segment is due to its most common method of producing flu vaccines through an egg-based manufacturing process that has been used for more than 70 years.
Route of Administration Insights
Based on route of administration, the influenza vaccines market is segmented into injection and nasal spray. The injection segment is likely to hold a larger market share in 2022. The same segment is expected to register a higher CAGR during the forecast period.
The market growth of the injection segment is attributed to the fact that it is the most common method for flu vaccine administration.
Key Topics Covered:
1. Introduction
2. Influenza Vaccines Market - Key Takeaways
3. Research Methodology
4. Influenza Vaccines Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. Global Influenza Vaccines Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Government Support to Promote Influenza Vaccination
5.1.2 Increasing Investment by Top Market Players and Governments
5.2 Market Restraints
5.2.1 High Cost of Vaccine Development
5.3 Market Opportunities
5.3.1 Emerging Economies
5.4 Future Trends
5.4.1 Strong Pipeline Candidates for Influenza Vaccines
5.5 Impact Analysis
6. Influenza Vaccine Market -Global Analysis
6.1 Global Influenza Vaccines Market Revenue Forecasts And Analysis
6.2 Global Influenza Vaccines Market, By Geography - Forecasts And Analysis
6.3 Global Influenza Vaccines Market - Market Potential Analysis, By Region
6.4 Company Analysis
6.4.1 Market Positioning of Key Players
6.4.2 Comparative Company Analysis
6.5 Growth Strategy Analysis
6.6 Performance of Key Players
6.6.1 Sanofi
6.6.2 SEQIRUS
7. Influenza Vaccines Market Analysis and Forecasts To 2028 - By Vaccine Type
7.1 Overview
7.2 Global Influenza Vaccines Market, By Vaccine Type 2022 & 2028 (%)
7.3 Quadrivalent Vaccines
7.4 Trivalent Vaccines
8. Influenza Vaccines Market Analysis and Forecasts To 2028 - By Virus Type
8.1 Overview
8.2 Global Influenza Vaccines Market, By Virus Type 2022 & 2028 (%)
8.3 Influenza Virus Type A
8.4 Influenza Virus Type B
9. Influenza Vaccines Market Analysis and Forecasts To 2028 - By Technology
9.1 Overview
9.2 Global Influenza Vaccines Market, By Technology 2022 & 2028 (%)
9.3 Egg-based
9.4 Cell-based
10. Influenza Vaccines Market Analysis and Forecasts To 2028 - By Route of Administration
10.1 Overview
10.2 Global Influenza Vaccines Market, By Route of Administration 2022 & 2028 (%)
10.3 Injection
10.4 Nasal Spray
11. Influenza Vaccines Market Analysis and Forecasts To 2028 - Geographical Analysis
12. Impact of COVID-19 Pandemic on Global Influenza Vaccines Market
13. Influenza Vaccine Market -Industry Landscape
13.1 Overview
13.2 Growth Strategies in the Influenza Vaccine Market, 2021-2028
13.3 Inorganic Growth Strategies
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Key Facts
14.2 Business Description
14.3 Products and Services
14.4 Financial Overview
14.5 SWOT Analysis
14.6 Key Developments
Moderna, Inc.
SEQIRUS
Sanofi
GlaxoSmithKline plc.
Hualan Biological Engineering Inc.
Emergent BioSolutions Inc.
Mitsubishi Chemical Group Corporation
Serum Institute of India Pvt. Ltd
MYLAN N.V.
AstraZeneca
For more information about this report visit https://www.researchandmarkets.com/r/m3os4x
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
